Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Pins Cladribine Hopes On Ongoing Studies After "Complete Response" Letter

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Merck KGaA is hoping data from already completed and ongoing studies will satisfy FDA's need to better understand the risk-benefit profile for its oral multiple sclerosis therapy cladribine, after the agency issued a "complete response" March 2.

You may also be interested in...



Merck KGaA 2010 Results Marred By Cladribine And Poor OTC Growth

Millipore acquisition boosts 2010 results for Germany's Merck, but pharma strategy remains unclear.

Novartis' Gilenya Shines Amid Bleak Day for MS Drugs In Europe

European regulators rebuff Fampyra and Movectro, but approve Gilenya.

EU Regulators Reject Merck KGaA's Oral MS Drug Cladribine

Surprise rejection hits German drugmaker hard and casts doubt over FDA approval.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004697

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel